Search hospitals > California > Whittier
The Oncology Institute of Hope and Innovation
Claim this profileWhittier, California 90603
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Cancer
Conducts research for Autoimmune Hemolytic Anemia
48 reported clinical trials
7 medical researchers
Summary
The Oncology Institute of Hope and Innovation is a medical facility located in Whittier, California. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Cancer, Autoimmune Hemolytic Anemia and other specialties. The Oncology Institute of Hope and Innovation is involved with conducting 48 clinical trials across 56 conditions. There are 7 research doctors associated with this hospital, such as Omkar S Marathe, Richy Agajanian, MD, Amitabha Mazumder, and Paul La Porte.Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Lung Cancer
Stage IV
Stage III
PD-L1 positive
Top PIs
Omkar S MaratheThe Oncology Institute of Hope and Innovation3 years of reported clinical research
Studies Colorectal Cancer
Studies Non-Small Cell Lung Cancer
18 reported clinical trials
31 drugs studied
Richy Agajanian, MDInnovative Clinical Research Institute8 years of reported clinical research
Studies Lymphoma
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
20 drugs studied
Amitabha MazumderThe Oncology Institute of Hope and Innovation5 years of reported clinical research
Studies Lymphoma
Studies Multiple Myeloma
9 reported clinical trials
19 drugs studied
Paul La PorteGSK Investigational Site3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Breast Cancer
10 reported clinical trials
18 drugs studied
Clinical Trials running at The Oncology Institute of Hope and Innovation
Non-Small Cell Lung Cancer
B-Cell Lymphoma
Lung Cancer
Lymphoma
Diffuse Large B-Cell Lymphoma
Paroxysmal Nocturnal Hemoglobinuria
Pancreatic Cancer
Solid Tumors
Prostate Cancer
Hemoglobinuria
Dato-DXd + Pembrolizumab
for Advanced Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Recruiting2 awards Phase 313 criteria
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
HBI-2438
for Cancer with KRAS G12C Mutation
This trial tests HBI-2438, an oral drug for patients with advanced solid tumors having the KRAS G12C mutation. The drug aims to stop cancer growth by blocking the faulty gene. Related drugs, Adagrasib and Sotorasib, have shown effectiveness in treating similar conditions.
Recruiting1 award Phase 16 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Oncology Institute of Hope and Innovation?
The Oncology Institute of Hope and Innovation is a medical facility located in Whittier, California. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Cancer, Autoimmune Hemolytic Anemia and other specialties. The Oncology Institute of Hope and Innovation is involved with conducting 48 clinical trials across 56 conditions. There are 7 research doctors associated with this hospital, such as Omkar S Marathe, Richy Agajanian, MD, Amitabha Mazumder, and Paul La Porte.